通过向 HIV-1 逆转录酶入口通道扩展发现二聚抑制剂。
Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.
机构信息
Department of Chemistry, Yale University, New Haven, CT 06520, USA.
出版信息
Bioorg Med Chem Lett. 2012 Feb 15;22(4):1565-8. doi: 10.1016/j.bmcl.2011.12.132. Epub 2012 Jan 5.
Abstract
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase is being pursued with computational guidance. Extension of azine-containing inhibitors into the entrance channel between Lys103 and Glu138 has led to the discovery of potent and structurally novel derivatives including dimeric inhibitors in an NNRTI-linker-NNRTI motif.
摘要
设计非核苷类 HIV-1 逆转录酶抑制剂正在通过计算指导进行。将含氮杂环抑制剂扩展到 Lys103 和 Glu138 之间的入口通道中，导致发现了包括 NNRTI-连接子-NNRTI 基序中的二聚抑制剂在内的有效且结构新颖的衍生物。
相似文献
1
Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2012 Feb 15;22(4):1565-8. doi: 10.1016/j.bmcl.2011.12.132. Epub 2012 Jan 5.
2
Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Bioorg Med Chem Lett. 2008 Feb 1;18(3):1131-4. doi: 10.1016/j.bmcl.2007.11.127. Epub 2007 Dec 5.
3
Synthesis and anti-HIV activity of some heterodimers [NRTI]-glycyl-succinyl-[trovirdine analogue] of known HIV-1 reverse transcriptase inhibitors.
J Enzyme Inhib Med Chem. 2003 Apr;18(2):175-86. doi: 10.1080/1475636032000069846.
4
Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.
J Med Chem. 2012 Apr 26;55(8):3595-613. doi: 10.1021/jm200990c. Epub 2012 Feb 15.
5
Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4824-4827. doi: 10.1016/j.bmcl.2015.06.074. Epub 2015 Jul 9.
6
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
J Med Chem. 2004 Feb 26;47(5):1175-82. doi: 10.1021/jm030255y.
7
Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Bioorg Med Chem. 2016 Jun 1;24(11):2519-2529. doi: 10.1016/j.bmc.2016.04.018. Epub 2016 Apr 8.
8
Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
J Med Chem. 2016 Mar 10;59(5):1891-8. doi: 10.1021/acs.jmedchem.5b01430. Epub 2016 Feb 3.
9
Development of nonnucleoside HIV reverse transcriptase inhibitors.
Methods Enzymol. 1996;275:440-72. doi: 10.1016/s0076-6879(96)75026-7.
10
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
J Med Chem. 2004 Nov 18;47(24):5923-36. doi: 10.1021/jm040072r.
引用本文的文献
1
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years.
Acta Pharm Sin B. 2020 Jun;10(6):961-978. doi: 10.1016/j.apsb.2019.11.010. Epub 2019 Nov 21.
2
Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Acta Pharm Sin B. 2020 Feb;10(2):344-357. doi: 10.1016/j.apsb.2019.09.007. Epub 2019 Oct 17.
3
Unbinding Dynamics of Non-Nucleoside Inhibitors from HIV-1 Reverse Transcriptase.
J Phys Chem B. 2019 Feb 28;123(8):1741-1748. doi: 10.1021/acs.jpcb.8b10341. Epub 2019 Jan 3.
4
Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.
ACS Med Chem Lett. 2018 Feb 27;9(4):334-338. doi: 10.1021/acsmedchemlett.7b00524. eCollection 2018 Apr 12.
5
Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.
Mol Pharmacol. 2017 Apr;91(4):383-391. doi: 10.1124/mol.116.107755. Epub 2017 Feb 6.
6
Computer-aided discovery of anti-HIV agents.
Bioorg Med Chem. 2016 Oct 15;24(20):4768-4778. doi: 10.1016/j.bmc.2016.07.039. Epub 2016 Jul 21.
7
Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.
Int J Mol Sci. 2015 Aug 18;16(8):19553-601. doi: 10.3390/ijms160819553.
8
A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase.
Biochim Biophys Acta. 2014 Jul;1840(7):2203-11. doi: 10.1016/j.bbagen.2014.04.001. Epub 2014 Apr 12.
9
Discovery of novel inhibitors of HIV-1 reverse transcriptase through virtual screening of experimental and theoretical ensembles.
Chem Biol Drug Des. 2014 May;83(5):521-31. doi: 10.1111/cbdd.12277. Epub 2014 Mar 24.
10
Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
Bioorg Med Chem Lett. 2013 Sep 15;23(18):5213-6. doi: 10.1016/j.bmcl.2013.06.091. Epub 2013 Jul 8.
本文引用的文献
1
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
J Med Chem. 2011 Dec 22;54(24):8582-91. doi: 10.1021/jm201134m. Epub 2011 Nov 29.
2
[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.
Bioorg Med Chem. 2010 Jul 1;18(13):4661-73. doi: 10.1016/j.bmc.2010.05.025. Epub 2010 May 11.
3
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
Bioorg Med Chem Lett. 2010 Apr 15;20(8):2485-8. doi: 10.1016/j.bmcl.2010.03.006. Epub 2010 Mar 4.
4
Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
Ann Pharmacother. 2010 Jan;44(1):157-65. doi: 10.1345/aph.1M359. Epub 2009 Dec 8.
5
The search for potent, small molecule NNRTIs: A review.
Bioorg Med Chem. 2009 Aug 15;17(16):5744-62. doi: 10.1016/j.bmc.2009.06.060. Epub 2009 Jul 3.
6
Efficient drug lead discovery and optimization.
Acc Chem Res. 2009 Jun 16;42(6):724-33. doi: 10.1021/ar800236t.
7
Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase.
Bioorg Med Chem Lett. 2008 Feb 15;18(4):1293-6. doi: 10.1016/j.bmcl.2008.01.025. Epub 2008 Jan 11.
8
The design of drugs for HIV and HCV.
Nat Rev Drug Discov. 2007 Dec;6(12):1001-18. doi: 10.1038/nrd2424.
9
HIV drug development: the next 25 years.
Nat Rev Drug Discov. 2007 Dec;6(12):959-66. doi: 10.1038/nrd2336.
10
Rationally designed dual inhibitors of HIV reverse transcriptase and integrase.
J Med Chem. 2007 Jul 26;50(15):3416-9. doi: 10.1021/jm070512p. Epub 2007 Jul 4.
Zotero 插件